BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a biotech company specialized in the development of diagnostic tests for the early detection of cancers and genetic diseases, will host a first R&D Day on May 10th, 2017, in the Imagine Institute (Necker Hospital, Paris).
This event dedicated to the investors, the analysts and the press will allow them to deepen their knowledge on the main GENOMIC VISION’s R&D programs through presentations led with its historical industrial partner QUEST DIAGNOSTICS and several academic teams.
The program of the R&D Day includes the following presentations:
9h30: Inaugural speech
Aaron Bensimon – CEO of GENOMIC VISION
9h45: Pediatric Spinal Muscular Atrophy – SMA program presentation
Pr Arnold Munnich, Head of Genetic Service at the Necker Hospital - Enfants-Malades
10h15: “Quest Diagnostics genetic testing frontiers and DNA combing
Jay Wohlgemuth, Senior VP, CMO of Quest Diagnostics
Edward Ginns, M.D, Ph.D, Medical director – Neurology - Quest Diagnostics
10h45: Myopathy: Facioscapulohumeral Muscular
Dystrophy – “(R)Evolution of Diagnostic approaches in FSHD1 towards
multi-allelic determination by molecular combing”
Pr Nicolas Levy, Head of Medical Genetics department at the Children's Hospital La Timone (Marseille, France)
11h15: Cervical Cancer Diagnostic and Prognostic– Presentation of
the HPV program conducted in Czech Republic
Dr. Vladimír Dvořák, Brno Centre for Outpatient Gynecology and Primary Care), principal investigator of the HPV pilot study
Dr Petr Janda, CEO of PCS (Prague Clinical Services)
11h45: Round-table hosted by Fabrice Papillon:
“Which strategies for the screening of the genetic diseases in the future? What pathologies in sights? "
Aaron Bensimon, CEO of Genomic Vision, declared: “We are very honored to invite our investors, financial analysts and the press to this event to present in detail all of our clinical diagnostic programs notably with the presence of Quest Diagnostics, our historic industrial partner. I hope that this R&D Day will serve to highlight in detail Genomic Vision’s technological and commercial strategy. Finally, these scientific and medical presentations will underline the acceleration of our innovations and our partnerships. This acceleration is an important measure of short, medium and long-term value creation”.
In addition, GENOMIC VISION will organize a second R&D Day in next autumn during which the management team will present the advantages of our technology in the field of Life Sciences Research, particularly in safety control in the gene editing and DNA replication.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotech company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the DNA
Molecular Combing, a strong proprietary technology allowing to identify
genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of
the pharmaceutical companies, the leaders of the diagnostic industry and
the research labs.
The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 60 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV - ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of CAC® Mid & Small and CAC® All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on April 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.